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A rapidly expanding catalogue of neurogenetic disorders has encouraged a diagnostic shift 
towards early clinical whole exome sequencing (WES). Adult primary mitochondrial diseases 
(PMDs) frequently exhibit neurological manifestations that overlap with other nervous 
system disorders. However, mitochondrial DNA (mtDNA) is not routinely analyzed in standard 
clinical WES bioinformatic pipelines. We reanalyzed 11,424 exomes, enriched with 
neurological diseases, for pathogenic mtDNA variants. Twenty-four different mtDNA 
mutations were detected in 64 exomes, 11 of which were considered disease causing based 
on the associated clinical phenotypes. These findings highlight the diagnostic uplifts gained 





















The rapid expansion in recognised inherited neurological disorders has led to a “genetics first” 
approach to their diagnosis, which frequently involves the early application of clinical whole 
exome sequencing (WES)1. There is also growing evidence that the iterative reanalysis of 
exome data significantly improves the diagnostic yield of pathogenic DNA variants in rare 
diseases, and should therefore be considered in all unresolved cases2. 
 
Primary mitochondrial diseases (PMDs) have an adult prevalence of 1 in 4,3003, thus 
represent some of the most common neurogenetic disorders, and frequently manifest with 
nervous system phenotypes that overlap with other neurological disorders. More than 300 
mitochondrial proteins, encoded by both nuclear and mitochondrial genomes, are linked with 
PMDs4; however, mitochondrial DNA (mtDNA) mutations account for the vast majority in 
adults3. Importantly, although mtDNA reads are generated during WES they are not routinely 
analyzed. Consequently, standard clinical WES bioinformatic pipelines do not report disease 
causing mtDNA variants.  
 
We applied a GenomeAnalysisToolkit (GATK) Mutect2-based5, 6 bioinformatics pipeline to 
analyze the mtDNA reads from 11,424 exomes, generated by University College London 
Queen Square Genomics Facility, and determined the diagnostic uplifts gained by including 










The study was approved by the Queen Square Research Ethics Committee, London 
(09/H0716/76). 
 
Ascertainment of whole exome sequencing data and cohort phenotypic groups 
In total, 11,424 DNA samples, extracted from blood, which had undergone WES analysis at 
the University College London Queen Square Genomics Facility between 2011 and 2019 were 
included in the study. The cohort was composed of probands with a range of neurological 
phenotypes, their relatives and healthy controls. The most common clinical group comprised 
extrapyramidal and movement disorders (International Classification of Disease-10 code G20-
G26)7 (31.5%), followed by systemic atrophies, primarily affecting the central nervous system 
(G10-G14) (17%), episodic and paroxysmal disorders (G40-G47) (16.4%), diseases of 
myoneural junction and muscle (G70-G73) (7.5%), other degenerative diseases of the nervous 
system (G30-G32) (7.4%), polyneuropathies and other disorders of the peripheral nervous 
system (G60-G64) (3.6%), and mitochondrial metabolism disorders (E88.4) (1.4%). 
Neurologically normal controls accounted for 15.2% of the exomes. 
 
Mitochondrial variant calling and filtering 
Exome capture libraries were generated using SureSelect (Agilent), Nextera (Illumina) or 
TrueSeq (Illumina) kits, and all samples were sequenced using Illumina instruments 
generating 100-150bp paired-end reads. Fastq files were aligned to the GRCh38 genome 
reference, which includes the revised Cambridge Reference Sequence (rCRS) of human 
mtDNA, using NovoAlignV3.08.02 (Novocraft). Alignments were further processed according 
to the GATKv4 best practices5 and variants in mtDNA were called using a somatic variant 
caller, Mutect26, in tumor-only mode and filtered using FilterMutectCalls tool. Only variants 
in exomes with an average mtDNA coverage of ≥10x were kept for downstream analysis 
(Figure 1) and annotated using Variant Effect Predictor8, Mitomap9 and an in-house database 
of mtDNA variants. Variants of interest were defined as those with a “confirmed” pathogenic 
status in Mitomap. Variants with a read depth ≥10x and heteroplasmy level of ≥10% in blood 





Confirmation of pathogenic mitochondrial DNA variants 
All pathogenic mtDNA variants identified from WES data were subsequently confirmed using 
whole mtDNA next generation sequencing (NGS). Long-range PCR amplification of two 
overlapping fragments covering the entire mtDNA preceded NGS on the MiSeq platform using 
the Illumina NextEra XT library preparation. Data analysis was performed using an in-house 
pipeline aligned to the rCRS, GenBank accession number NC_012920.1. Coverage of the 
coding region (nucleotides 577-16023) was at a minimum depth of 1000x. Variant detection 
sensitivity was greater than 95% (95% confidence interval).  
 
Classification of pathogenic mitochondrial DNA variants 
Pathogenic mtDNA variants were stratified according to their associated neurological 
presentations as follows: 1) Clinically significant pathogenic mtDNA variants, defined as a 
well-recognised/reported clinical phenotype and a mutant mtDNA heteroplasmy level of 
≥10% in blood; 2) Pathogenic mtDNA variants of undetermined clinical relevance, defined as 
an atypical clinical phenotype and a mutant mtDNA heteroplasmy level of ≥10% in blood; and 
3) Pathogenic mtDNA variants that exhibit variable clinical penetrance at near homoplasmic 
or homoplasmic mutant levels and a mutant mtDNA heteroplasmy level of ≥10% in blood 




In total, 6,175 mitochondrial variants were identified across 10,121 exomes with sufficient 
mtDNA coverage (median mtDNA coverage = 43.9x; Figure 1). This included 28 pathogenic 
mtDNA variants in 83 exomes. Twenty-four variants in 64 exomes met our threshold for 
further clinical evaluation; specifically, a locus-specific depth ≥10x and a heteroplasmy level 
≥10% (Table 1-3 and Supplementary Table 2).  
 
Clinically significant pathogenic mitochondrial DNA variants 
Clinically significant pathogenic mtDNA variants were detected in 11 exomes from 9 unrelated 
families (mean age 36 years; age range 3-82 years; 36% female, Tables 1 and 2). The variants 
broadly resided within two groups of genes: seven pathogenic variants were detected in 
mitochondrial complex I subunit genes (MT-ND1, MT-ND3, MT-ND5, and MT-ND6); and four 
 
 
pathogenic variants resided in MT-ATP6, encoding the ATP6 subunit of mitochondrial ATP 
synthase (complex V). Mutant levels of the MT-ATP6 variants were uniformly high in blood 
(92-98%). This corresponded to predominantly central nervous system (CNS) phenotypes, 
including Leigh syndrome (LS) and Leigh-like syndrome, which typically occur when the 
mutant load is ≥90%10. One individual survived into the 9th decade despite harbouring 98% 
m.8851T>C levels, a mutant load previously linked with severe paediatric phenotypes11, 12. 
Mutant mtDNA levels in exomes with pathogenic complex I subunit variants were more 
variable in blood (14-97%). There was also a less obvious correlation between the clinical 
phenotype and the underlying mutant load, given that all patients had severe CNS phenotypes 
(LS/Leigh-like syndrome and mitochondrial encephalomyopathy, lactic acidosis and stroke-
like episodes, MELAS), despite some harbouring relatively low heteroplasmy levels in blood. 
Variable neurological manifestations have previously been reported with low mutant MT-ND5 
levels13, thus reaffirming that pathogenic mtDNA variants measured peripherally (even in 
post-mitotic tissues) do not always accurately reflect CNS levels. 
 
Pathogenic mitochondrial DNA variants of undetermined clinical relevance 
Pathogenic mtDNA variants with undetermined clinical relevance were detected in 12 exomes 
from 12 unrelated families (Table 3). The variants were located in mitochondrial tRNA genes 
(MT-TL1, MT-TS1, and MT-TK), MT-ATP6 and complex I subunit genes (MT-ND4 and MT-ND5). 
The range of mutant mtDNA levels in blood were as follows: mitochondrial tRNA genes (29-
98%); MT-ATP6 (21-58%); and complex I subunit genes (28-73%). None of the clinical 
manifestations reported were typical for the well-recognised phenotypes associated with the 
detected pathogenic mtDNA variants, and in some instances, an alternative diagnosis was 
confirmed pathologically (Subjects 15, 16 and 17) or genetically (Subject 14). Furthermore, 
one patient (Subject 12) had a clinicopathological diagnosis of inclusion body myositis, despite 
harbouring 98% mutant levels of the pathogenic m.3243A>G variant in MT-TL1 associated 
with MELAS, and we are currently investigating the potential protective mechanisms 
preventing PMDs from manifesting in this individual. 
 
Pathogenic mitochondrial DNA variants with variable clinical penetrance 
Pathogenic mtDNA variants that exhibit variable clinical penetrance were detected in 41 
exomes. This group comprised mtDNA mutations associated with LHON (n=12), deafness 
 
 
and/or aminoglycoside-induced deafness (n=27) and maternally inherited cardiomyopathy 
(n=2) (Supplementary Table 2). None of the patients (apart from Subject 50) exhibited visual 
failure, deafness or cardiomyopathy, despite many carrying near homoplasmic or 
homoplasmic mutant mtDNA levels. Subject 50 had bilateral sensorineural hearing loss 
associated with a complex neurological phenotype that would not be accounted for by the 
m.1555A>G mtDNA mutation alone. The absence of clinical manifestations, despite many 
patients harbouring near homoplasmic or homoplasmic mutant mtDNA levels, is in keeping 
with the variable penetrance characteristic of these recurrent mtDNA variants14. 
 
DISCUSSION 
Reanalysis of 11,424 exomes identified 24 unique pathogenic mtDNA variants across 64 
exomes. Clinically significant pathogenic mtDNA variants were detected in 11 exomes from 
nine unrelated families, thus confirming an mtDNA-related PMD diagnosis in these patients. 
Of these 11 individuals, PMD had been considered in six (Subjects 4-9), but mtDNA analysis 
was not completed prior to WES. This was partly due to the absence of characteristic 
mitochondrial abnormalities observed in muscle (Subjects 6 and 7), but also the limited access 
to diagnostic mtDNA NGS at the local recruiting centres. In five of the 11 patients, a PMD 
diagnosis was not contemplated prior to WES despite phenotypes that, in hindsight, were 
compatible with the underlying pathogenic mtDNA variants subsequently detected. These 
findings highlight the major challenges faced by neurologists when evaluating patients with 
PMDs, which results from the clinical overlap that exists between PMD phenotypes and other 
neurological disorders. There has also been a shift towards a “genetics first” approach to 
diagnosing genetic neurological diseases, through the application of large nuclear gene panels 
and WES. However, mtDNA analysis is not routinely included in standard clinical WES 
bioinformatic pipelines, despite pathogenic mtDNA (rather than nuclear DNA) variants 
accounting for the majority of adult PMDs.3 Consequently, including mtDNA analysis when 
evaluating neurological disease exomes represents an opportunity to capture genetically 
undiagnosed mtDNA-related PMDs. Importantly, mtDNA NGS of a post-mitotic tissue (e.g., 
skeletal muscle) remains the “gold standard” molecular approach for excluding pathogenic 




Muscle histopathology was available in four patients in whom PMD had been considered prior 
to WES; two (Subjects 4 and 9) demonstrated the typical pathological hallmarks of PMD 
(ragged red and/or cytochrome c oxidase negative fibers), one exhibited a mild increase in 
lipid deposition only, albeit associated with reduced mitochondrial respiratory chain complex 
I enzyme activity (Subject 6), and one was normal (Subject 7). The most common brain MRI 
findings in patients with clinically significant pathogenic mtDNA variants included signal 
abnormalities of the basal ganglia and brainstem, in patients with Leigh/Leigh-like syndrome 
(Subjects 4, 7, 8, and 9) and MELAS (Subject 6), and cerebellar atrophy (Subjects 2, 4 and 5). 
Diffuse white matter changes were also observed in two patients (Subjects 6 and 9). 
 
Pathogenic mtDNA variants of undetermined clinical relevance were detected in 12 exomes 
from 12 unrelated families, while 41 exomes contained pathogenic mtDNA variants known to 
exhibit variable penetrance, despite near homoplasmic or homoplasmic mutant levels. The 
latter included pathogenic mtDNA variants associated with LHON (n=12), deafness and/or 
aminoglycoside-induced deafness (n=27), and cardiomyopathy (n=2). There was no evidence 
to suggest an underlying PMD in these individuals, and mutant mtDNA levels for some 
variants were below the threshold necessary for clinical symptoms to manifest (with the 
caveat that they were all detected in blood). However, there remains the possibility that 
disease onset could occur later in life or that subclinical manifestations are present (e.g., 
cardiomyopathy or cardiac conduction defects). These findings have therefore been 
confirmed by diagnostic mtDNA NGS, with further analysis of a second tissue to assess risk, 
where appropriate. Reporting of secondary actionable findings (i.e., genetic variants causing 
risk of an unrelated disease that would affect patient management) in large-scale genetic 
testing is not straightforward, and mtDNA encoded genes are not currently included in the 
American College of Medical Genetics and Genomics (ACMG) medically actionable genes 
list15, 16. However, the finding of a pathogenic mtDNA variant that potentially explains part or 
all of a clinical phenotype is within the remit of a primary finding, given it addresses the 
medical basis for requesting the test. There is no uniform definition of what is ‘medically 
actionable’.17 Consequently, when a pathogenic mtDNA variant did not clearly contribute 
towards the disease (Table 3), the recruiting clinician was informed to determine whether it 
was actionable for that individual and whether the patient’s consent supported reporting of 
secondary findings.  
 
 
One limitation of mtDNA analysis using WES data is the depth of mtDNA coverage achieved. 
Unlike clinical diagnostic laboratories, which use dedicated deep sequencing of mtDNA18, 
WES achieves comparatively low coverage of extracted mtDNA reads. Consequently, low-
level heteroplasmic mtDNA variants, particularly in blood, might remain undetected, despite 
the presence of higher, clinically relevant levels in post-mitotic tissues. A second potential 
limitation is the spurious identification of a variant within a nuclear pseudogene that closely 
resembles an mtDNA gene – a so called “nuclear mitochondrial DNA segments” or “NUMTs”19. 
However, we simultaneously aligned reads to nuclear and mitochondrial genomes and 
confirmed pathogenic mtDNA variants by sequencing long-range PCR enriched mtDNA, thus 
the risk of such errors is extremely low20. 
 
In conclusion, exome reanalysis for pathogenic mtDNA variants in our cohort achieved a 
diagnostic uplift in 11 patients, thus highlighting the importance of including mtDNA analysis 
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Figure 1: Flow diagram summarising sample-level and variant-level filtering steps applied to 
11,424 samples that underwent exome sequencing analysis at the University College London 
Queen Square Genomics Facility between 2011 and 2019. The figure was created using 
BioRender.com. Abbreviation: mtDNA, mitochondrial DNA. 
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Table 1: Clinically significant pathogenic mitochondrial DNA variants detected in the 11,424 exomes 
analyzed
Abbreviations: BSN, bilateral striatal necrosis; het, heteroplasmy; LDYT, Leber hereditary optic 
neuropathy and dystonia; LHON, Leber hereditary optic neuropathy; LS, Leigh syndrome; MELAS, 
mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes; MILS, maternally 
inherited Leigh syndrome; mtDNA, mitochondrial DNA; NARP, neurogenic muscle weakness, ataxia, and 
retinitis pigmentosa; PEO, progressive external ophthalmoplegia.




reads Het (%) Reported associated disease
9
1 m.3697G>A MT-ND1 7 89 92 MELAS /  LS / LDYT
2 m.8851T>C MT-ATP6 1 61 98 BSN / LS
3 m.8993T>C MT-ATP6 0 65 98 NARP / LS / MILS / other
4 m.9185T>C MT-ATP6 1 76 97 LS / Ataxia syndromes / NARP-like disease
5 m.9185T>C MT-ATP6 7 96 92 LS / Ataxia syndromes / NARP-like disease
6 m.10158T>C MT-ND3 19 6 25 LS / MELAS
7 m.13094T>C MT-ND5 87 55 39 Ataxia and PEO / MELAS, LS, myoclonus, fatigue
8 m.13513G>A MT-ND5 47 54 53 LS / MELAS / LHON-MELAS overlap syndrome
9 m.13513G>A MT-ND5 19 3 14 LS / MELAS / LHON-MELAS overlap syndrome
10 m.14459G>A MT-ND6 1 83 96 LDYT / LS
11 m.14459G>A MT-ND6 2 78 97 LDYT / LS










Table 2: Clinical features of the patients with clinically significant pathogenic mitochondrial DNA 
variants in the 11,424 exomes analyzed
Abbreviations: ADHD, attention deficit hyperactivity disorder; CSF, cerebrospinal fluid; ID, intellectual 
disability; INO, intra-nuclear ophthalmoplegia; LS, Leigh syndrome; LVH, left ventricular hypertrophy; 
MRI, magnetic resonance imaging; NA, not available; RBBB, right bundle branch block; RCEA, respiratory 





Subject phenotype Muscle pathology and RCEA Brain MRI Family history
1 3/m
Encephalopathy, lower limb spasticity, 









cerebellar atrophy and 
sparing of the brainstem
Identical twin brother with ataxia
3 13/m Developmental delay, spastic-dystonic gait, ID, axonal neuropathy NA NA
One older sibling with 
developmental delay and ID
4 45/mDeceased
Young adult onset progressive cerebellar 
ataxia, tremor, optic atrophy, neuropathy, 
myoclonic epilepsy, urinary frequency,  
atrial fibrillation
RRF
Basal ganglia changes 
and cerebellar atrophy
One affected brother (Subject 5), 
mother asymptomatic (47% 
mutant load in blood), maternal 
grandmother with epilepsy
5 49/m
Young adult onset progressive cerebellar 
ataxia, pyramidal signs, neuropathy, 
restless leg syndrome, ADHD
NA Marked cerebellar atrophy
Less severely affected brother of 
Subject 4
6 29/f
Stroke-like episodes, cerebellar ataxia, left 
sided spastic hemiparesis, learning 
difficulties,  seizures, optic atrophy, mild 
scoliosis, incomplete RBBB
Mild increase in 
lipid, no RRF or 
COX negative fibers
Low complex I
White matter changes 
and high signal in right 





Encephalopathic episode with bilateral INO 
and diplopia, nocturnal hypoventilation, 






peduncular T2 signal 
hyperintensities
Mother and two brothers 
asymptomatic
8 26/f
LS, learning disability, limb dystonia, 
regression of mobility and speech after the 
age of 9, raised CSF lactate
NA Basal ganglia lesions Mother asymptomatic
9 20/fDeceased
Focal epilepsy, mild ID, failure to thrive, 





symmetrical T2 high 
signal in basal ganglia, 




10 52/f Cognitive abnormalities, slowly progressive gait changes with onset at 30 years NA NA One affected brother (Subject 11)
11 45/mDeceased Gait changes with onset at 20 years NA NA One affected sister (Subject 10)










Table 3: Pathogenic mitochondrial DNA variants of undetermined clinical relevance in the 11,424 
exomes analyzed
Abbreviations: ASD, autistic spectrum disorder; BSN, bilateral striatal necrosis; CPEO, chronic progressive 
external ophthalmoplegia; DM, diabetes mellitus; DMDF, diabetes deafness; EXIT, exercise intolerance; 
FBSN, familial bilateral striatal necrosis; FSGS, focal segmental glomerulosclerosis; HCM, hypertrophic 
cardiomyopathy; Het, heteroplasmy; IBM, inclusion body myositis; LHON, Leber hereditary optic 
neuropathy; LDYT, LHON and dystonia; LS, Leigh syndrome; MELAS, mitochondrial encephalomyopathy 
with lactic acidosis and stroke-like episodes; MERRF, Myoclonic epilepsy with ragged-red fibers; MIDD, 
Maternally inherited diabetes and deafness; MILS, maternally inherited Leigh syndrome; MM, 
















disease9 Subject phenotype / Investigations
12 77/f m.3243A>G MT-TL1 0 17 98
MELAS / LS / DMDF / 
MIDD / SNHL / CPEO / 




Onset of symptoms aged 40 years with grasp and 
proximal lower limb weakness
Muscle biopsy; endomysial inflammatory cell infiltrate 
with invasion of non-necrotic muscle fibres, fibres 
with rimmed vacuoles, ragged red and COX negative 
fibers
13 NA m.3243A>G MT-TL1 10 4 29
MELAS / LS / DMDF / 
MIDD / SNHL / CPEO / 
MM / FSGS / ASD / 
Cardiac and multiorgan 
dysfunction
Adult subject with brain calcifications, no family 
history
14 3/f m.3260A>G MT-TL1 7 16 68 MMC / MELAS
Hypotonia since birth, severe intellectual 
disability, stereotyped hand movements, choreic 
movements, dystonic postures, anarthria
MRI; thin corpus callosum with delayed myelination
Confirmed heterozygous VAMP2 mutation
15 NA m.3271T>C MT-TL1 51 20 30 MELAS / DM MSA; pathologically confirmed
16 NA m.7497G>A MT-TS1 32 26 45 MM / EXIT MSA; pathologically confirmed
17 NA m.8344A>G MT-TK 54 107 65
MERRF; Other - LS / 
Depressive mood disorder 
/ Leukoencephalopathy / 
HCM
MSA; pathologically confirmed
18 NA m.8851T>C MT-ATP6 22 5 21 BSN / LS Unaffected subject
19 NA m.8993T>G MT-ATP6 20 28 58
NARP / Leigh Disease / 
MILS / Other PD
20 NA m.9176T>C MT-ATP6 17 15 47 FBSN / Leigh Disease Unaffected subject
21 NA m.9185T>C MT-ATP6 16 5 25
Leigh Disease / Ataxia 
syndromes / NARP-like 
disease
Extrapyramidal disorder
22 NA m.11778G>A MT-ND4 4 11 73
LHON / Progressive 
dystonia PD
23 21/m m.13513G>A MT-ND5 69 27 28














mtDNA, mitochondrial DNA; NA, not available; NARP, neurogenic muscle weakness, ataxia, and retinitis 
pigmentosa; No., number; PD, Parkinson’s disease; SNHL, sensorineural hearing loss.
This article is protected by copyright. All rights reserved.
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